FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
To read the full story
Related Article
- FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk
June 14, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
ORGANIZATION
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026
- Japan Pharmacy Group Renews Call to Scrap Off-Year Drug Price Revisions
November 13, 2026
- JPMA to Draw Up 2027 Strategic Plan Based on Industry Vision
November 13, 2026
- JMA Renews Backing for Hanako Jimi in 2028 Upper House Race
November 11, 2026
- Rethink Labor Cost Calculations in Drug Pricing: Pharma Labor Group
November 5, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





